Bloomfield CVRI Early Career Award in Cardiovascular Research
This unique award, funded by an endowment from Martin Bloomfield, MD '60, provides support to early-stage, independent investigators in developing high quality and competitive cardiovascular research programs.  The planned investigation must be related to cardiovascular diseases and can be basic, clinical, translational, epidemiologic, or public health-related, and includes stroke.  Faculty from any UVM college who are in the initial 5 years of their first faculty appointment (assistant professor) will be considered.

The award recipient will receive funding for two consecutive years ($45,000 per year) with a possibility of a third year of support. There will be only one awardee at any given time.

Deadlines:  March 1, 2017 - Letter of Intent    &    April 15, 2017 - Application

For more information, please click on each of the Award documents:     Award Criteria         Application Instructions


A Mission to Foster Cardiovascular Research
The Cardiovascular Research Institute of Vermont (CVRI-VT) exists to foster cardiovascular research at The University of Vermont.  As an organization, CVRI is broadly inclusive of investigators at UVM who are pursuing cardiovascular research, and it includes and serves members of multiple departments.  Our key objectives are to:

  • improve communication, particularly across disciplines, departments, and colleges;
  • increase collaboration;
  • increase funding to support cardiovascular research; and
  • advance and highlight excellence in research nationally and internationally.


PhilAdes_EndowedProfessor

Phil Ades, MD Inaugural Endowed Professor

On December 16, 2016, Philip Ades, MD, professor of medicine, director of cardiac rehabilitation and preventive medicine, and a CVRI Distinguished Investigator, was honored as the inaugural Philip Ades, MD Professor of Cardiovascular Disease Prevention.  This professorship honors the significant impact of the cardiac rehabilitation and disease prevention work performed by Ades over his more than 30-year career at UVM.  Dedicated to improving the lives of patients with heart conditions, Ades has conducted world-class research on the important role exercise can play in rehabilitation after a heart attack and the benefits of weight loss in obese coronary heart disease patients. 

The Ades Endowed Professorship was made possible by donations from Ades and his wife, Deborah Rubin, MD, and by gifts from grateful patients, family members, and the estate of alumna Harriet Dustan '42, MD '44, a cardiologist and pioneer in the detection and treatment of hypertension. 

Click here for more information.  

Mary Cushman

Editor-In-Chief for New Journal

The International Society on Thrombosis and Haemostasis (ISTH) recently announced the launch of its new open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH), naming Mary Cushman, MD, MSc, as its inaugural Editor-In-Chief. Dr. Cushman, a member of the CVRI Board of Directors, is professor of medicine in the Hematology/Oncology Division of the UVM Department of Medicine and Director of the Thrombosis and Hemostasis Program at The UVM Medical Center.

RTPH will publish a broad array of article types covering the widest possible spectrum of topics in thrombosis, hemostasis, and related areas, including studies by multidisciplinary research groups from emerging areas of research and under-represented regions of the world as well as studies and trials covering quality of care, outcomes, and dissemination and implementation science.

Click here to visit the RPTH homepage.    

Warshaw Clerkship Lecture

Pioneering Heart Failure Discovery

More than 15 years ago, David Warshaw, PhD, and coworkers discovered the precise malfunction of a specific protein in the heart that leads to hypertrophic cardiomyopathy (HCM).  An inherited disease, HCM can cause the heart to thicken and stop pumping blood effectively, leading to heart failure.  Now, a team of scientists has used some of Warshaw’s earlier findings to develop a possible therapy to prevent HCM.  Warshaw, professor and chair of molecular physiology and biophysics at UVM and a Director of CVRI, wrote about the significance of this potential therapy for a “Perspectives” column in the February 5, 2016 issue of the journal Science.  “This may offer a generalized approach to solving hypertrophic cardiomyopathy,” says Warshaw.  “I think it’s extremely promising."

Read Dr. Warshaw’s column and the report from the team of scientists.


Trainees

CVRI can help connect trainees who would like to work on cardiovascular research projects with investigators doing cardiovascular research. 
Trainees - please e-mail CVRI with your research interests and we will reach out to our database of investigators.

News and Announcements

Applications for Travel Awards are now being accepted - click here for information and the application form. Your application must be received at least 30 days before the date of your presentation. 

CVRI provides internal review of grant applications to support cardiovascular research. E-mail CVRI for more information.  *NOTE: The request for internal review must be made at least 6 weeks before the submission deadline.

CVRI Annual Report

2015 AnnRep Cover

Through a summary of CVRI activities and a compilation of cardiovascular-related research and publication highlights, the CVRI Annual Report demonstrates the depth and breadth of the cardiovascular research being conducted at the University of Vermont and the UVM Medical Center. Click here to view the CVRI Annual Report for 2015.